Search
Search Results
-
Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis
BackgroundPneumonia is the most serious form of acute respiratory infection and Streptococcus pneumoniae is a leading cause of pediatric bacterial...
-
Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018
BackgroundInvasive pneumococcal disease (IPD) is a major cause of pediatric morbidity and mortality. Pneumococcal conjugate vaccines (PCVs) were...
-
Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England
BackgroundThe 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2006 and the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010...
-
Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
IntroductionThis study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization...
-
Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England
BackgroundPneumococcal disease is a leading cause of communicable disease morbidity and mortality globally. We aimed to estimate invasive...
-
Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018
BackgroundAcute otitis media (AOM) is a leading cause of office visits and antibiotic prescriptions in children. Pneumococcal conjugate vaccines were...
-
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis
IntroductionSince 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany’s Standing Committee on...
-
The remarkable history of pneumococcal vaccination: an ongoing challenge
Although it varies with age and geographical distribution, the global burden of infection with Streptococcus pneumoniae (pneumococcus) remains...
-
Prevalence and Resistance Patterns of Streptococcus pneumoniae Recovered from Children in Western Asia
Purpose of ReviewDespite the available pneumococcal conjugate vaccination (PCV), children in develo** countries suffer significant morbidity and...
-
20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval
20‑valent pneumococcal conjugate vaccine (PCV20; Prevnar 20 ® ; Apexxnar ® ) is a pneumococcal conjugate vaccine (PCV) developed by Pfizer for active...
-
Highly Resistant Serotype 19A Streptococcus pneumoniae of the GPSC1/CC320 Clone from Invasive Infections in Poland Prior to Antipneumococcal Vaccination of Children
IntroductionThe introduction of pneumococcal conjugate vaccines (PCV) into the national immunization programs (NIPs) has significantly reduced the...
-
Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden
BackgroundThe pneumococcal conjugate vaccine PCV7 was introduced in Southwest Sweden in the child vaccination program in 2009, followed by PCV13 in...
-
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions
IntroductionA 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the...
-
Disease Burden of Meningitis Caused by Streptococcus pneumoniae Among Under-Fives in China: A Systematic Review and Meta-analysis
IntroductionStreptococcus pneumoniae is the leading cause of meningitis, with a case fatality of up to about 50%. Children younger than 5 years are...
-
Effect of prophylactic administration of antipyretics on the immune response to pneumococcal conjugate vaccines in children: a systematic review
BackgroundProphylactic administration of antipyretics at the time of immunization seems to decrease some side effects, however reduced immune...
-
The effect of pneumococcal conjugated vaccines on occurrence of recurrent acute otitis media among infants diagnosed with acute otitis media at an age younger than 2 months
To examine the impact of pneumococcal conjugate vaccines (PCV) on the occurrence of recurrent acute otitis media (rAOM) among infants diagnosed with...
-
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
IntroductionThe 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix) was introduced into the Dutch pediatric national immunization program...
-
Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease
IntroductionPneumococcal disease, which presents a substantial health and economic burden, is prevented through pneumococcal vaccination programs. We...
-
Limited protection of pneumococcal vaccines against emergent Streptococcus pneumoniae serotype 14/ST876 strains
PurposeStreptococcus pneumoniae (Spn) is a major cause of child death. We investigated the epidemiology of S. pneumoniae in a pediatric fever clinic...
